These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 23219765

  • 1. Standard immunosuppressive therapy of immune-mediated glomerular diseases.
    Pani A.
    Autoimmun Rev; 2013 Jun; 12(8):848-53. PubMed ID: 23219765
    [Abstract] [Full Text] [Related]

  • 2. [Instructions and implementations for percutaneous renal biopsy. Guidelines for the therapy of glomerular nephropaties].
    Cagnoli L, Italian Society of Nephrology.
    G Ital Nefrol; 2003 Jun; 20 Suppl 24():S3-47. PubMed ID: 14666502
    [Abstract] [Full Text] [Related]

  • 3. Tacrolimus therapy in adults with steroid- and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR.
    Li X, Li H, Ye H, Li Q, He X, Zhang X, Chen Y, Han F, He Q, Wang H, Chen J.
    Am J Kidney Dis; 2009 Jul; 54(1):51-8. PubMed ID: 19406543
    [Abstract] [Full Text] [Related]

  • 4. [Immunosuppressive therapy of glomerulonephritis--controlled studies].
    Ferrari P, Frey FJ.
    Ther Umsch; 1993 Feb; 50(2):119-29. PubMed ID: 8456416
    [Abstract] [Full Text] [Related]

  • 5. Conventional treatment of idiopathic nephrotic syndrome and membranous nephropathy in adults.
    Ponticelli C, Passerini P.
    Clin Nephrol; 1991 Feb; 35 Suppl 1():S16-21. PubMed ID: 1860261
    [Abstract] [Full Text] [Related]

  • 6. B cell suppression in primary glomerular disease.
    Rood IM, Hofstra JM, Deegens JK, Wetzels JF.
    Adv Chronic Kidney Dis; 2014 Mar; 21(2):166-81. PubMed ID: 24602466
    [Abstract] [Full Text] [Related]

  • 7. Treatment of corticoresistant idiopathic nephrotic syndrome in the adult: minimal change disease and focal segmental glomerulosclerosis.
    Meyrier A, Simon P.
    Adv Nephrol Necker Hosp; 1988 Mar; 17():127-50. PubMed ID: 3124536
    [Abstract] [Full Text] [Related]

  • 8. Glomerular tip lesion: a distinct entity within the minimal change disease/focal segmental glomerulosclerosis spectrum.
    Stokes MB, Markowitz GS, Lin J, Valeri AM, D'Agati VD.
    Kidney Int; 2004 May; 65(5):1690-702. PubMed ID: 15086908
    [Abstract] [Full Text] [Related]

  • 9. Immunosuppressive treatment in the prevention of renal failure in primary glomerular diseases.
    Glassock RJ.
    Clin Exp Dial Apheresis; 1981 May; 5(1-2):21-46. PubMed ID: 7037247
    [Abstract] [Full Text] [Related]

  • 10. [Therapy of primary chronic glomerulonephritis].
    Risler T, Braun N, Erley CM.
    Ther Umsch; 1994 Dec; 51(12):807-12. PubMed ID: 7784993
    [Abstract] [Full Text] [Related]

  • 11. Rituximab use in adult glomerulopathies and its rationale.
    Santos JE, Fiel D, Santos R, Vicente R, Aguiar R, Santos I, Amoedo M, Pires C.
    J Bras Nefrol; 2020 Mar; 42(1):77-93. PubMed ID: 31904761
    [Abstract] [Full Text] [Related]

  • 12. Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trial.
    Bomback AS, Canetta PA, Beck LH, Ayalon R, Radhakrishnan J, Appel GB.
    Am J Nephrol; 2012 Mar; 36(1):58-67. PubMed ID: 22722778
    [Abstract] [Full Text] [Related]

  • 13. [Treatment of post-transplant glomerulonephritis].
    Sandrini S, Valerio F.
    G Ital Nefrol; 2008 Mar; 25 Suppl 44():99-106. PubMed ID: 19048593
    [Abstract] [Full Text] [Related]

  • 14. Use of Rituximab as an Off-Label Medication in Glomerular Diseases: Clinical Perspective.
    AlSahow A, Al-Muhaiteeb A, Nawar H, AlHelal B, AlYousef A, Abdallah E, AbuShall A, Elmekawi S, Meshal B, AlQallaf A, AlRajab H.
    Med Princ Pract; 2022 Mar; 31(2):133-141. PubMed ID: 35021170
    [Abstract] [Full Text] [Related]

  • 15. The Clinical Course of Minimal Change Nephrotic Syndrome With Onset in Adulthood or Late Adolescence: A Case Series.
    Maas RJ, Deegens JK, Beukhof JR, Reichert LJ, Ten Dam MA, Beutler JJ, van den Wall Bake AWL, Rensma PL, Konings CJ, Geerse DA, Feith GW, Van Kuijk WH, Wetzels JF.
    Am J Kidney Dis; 2017 May; 69(5):637-646. PubMed ID: 28089478
    [Abstract] [Full Text] [Related]

  • 16. Steroid-resistant nephrotic syndrome: long-term evolution after sequential therapy.
    Peña A, Bravo J, Melgosa M, Fernandez C, Meseguer C, Espinosa L, Alonso A, Picazo ML, Navarro M.
    Pediatr Nephrol; 2007 Nov; 22(11):1875-80. PubMed ID: 17876609
    [Abstract] [Full Text] [Related]

  • 17. Histopathological Spectrum and Short-Term Outcome of Treatment with Cyclophosphamide in Relapsing Steroid-Sensitive Nephrotic Syndrome.
    Bajeer IA, Khatri S, Tresa V, Hashmi S, Mubarak M, Lanewala AA.
    J Coll Physicians Surg Pak; 2018 Jun; 28(6):436-439. PubMed ID: 29848418
    [Abstract] [Full Text] [Related]

  • 18. Primary glomerulonephritides with nephrotic syndrome. Limitations of therapy in adult patients.
    Schena FP.
    J Nephrol; 1999 Jun; 12 Suppl 2():S125-30. PubMed ID: 10688412
    [Abstract] [Full Text] [Related]

  • 19. T helper (Th)-cytokines in the urine of patients with primary glomerulonephritis treated with immunosuppressive drugs: Can they predict outcome?
    Kalavrizioti D, Gerolymos M, Rodi M, Kalliakmani P, Provatopoulou S, Eleftheriadis T, Mouzaki A, Goumenos DS.
    Cytokine; 2015 Dec; 76(2):260-269. PubMed ID: 26307557
    [Abstract] [Full Text] [Related]

  • 20. Minimal change disease and focal segmental glomerulosclerosis in adults: response to steroids and risk of renal failure.
    Moura LR, Franco MF, Kirsztajn GM.
    J Bras Nefrol; 2015 Dec; 37(4):475-80. PubMed ID: 26648497
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.